Clinical Trials AVB500-OC-004/GOG-3059

AVB500-OC-004/GOG-3059: A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer. (AXLerate-OC)

A Clinical Trial for Ovarian cancer in

Covington

This is a randomize, double-blind Phase 3 study to compare the efficacy and safety of AVB-S6-500 in combination with paclitaxel (Pac) versus placebo in combination with Pac in patients with platinum resistant recurrent ovarian cancer.

Learn More

AVB500-OC-004/GOG-3059: A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer. (AXLerate-OC)

Helpful Links

Our Partners

What to know about ovarian and uterine cancer

AVB500-OC-004/GOG-3059: A Phase 3, Randomized, Double-Blind, Adaptive, Placebo/Paclitaxel-Controlled Study of AVB-S6-500 in Combination with Paclitaxel in Patients with Platinum-Resistant Recurrent Ovarian Cancer. (AXLerate-OC)